Document Type: Original Research

Authors

Dept. of Pathology, Imam Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran

Abstract

 
Background and Objectives: The most prevalent malignancy among women is known to be breast cancer (BC). Several factors contribute to determining tumor prognosis and treatment strategies. In this study, the frequency and relevance of these factors are discussed.
Materials and Methods: This cross-sectional study was carried out on 214 patients with BC, who referred to the Cancer Institute of Imam Hospital complex, Tehran, Iran in 2010 and 2011. The data about biomarkers (ER, PR, P53, HER-2) status and clinic pathologic features were extracted from patients files.
Results: Invasive ductal carcinoma (90.7%) was the most common pathology of BC. The frequency of estrogen receptor (ER), progesterone receptor (PR), P53 and HER2 was estimated as 63.6%, 58.9%, 37.4% and 21.9% respectively. None of these markers had significant relationship with age, tumor size, tumor pathology, vascular invasion, calcification, nipple invasion, benign component, skin invasion and mitosis. Between low grade histology of tumor and ER, PR significant positive relationship was found (P=0.001). Lymph node involvement was positively associated with P53 expression. A positive relationship found between ER and PR (P=0.001). Both P53 and HER-2 inversely correlate with ER, PR (P=0.001). HER2 and P53 had no significant relationship.
Conclusion: We found a significantly higher PR(+), ER(+) expression in low grade tumors. Although P53 and HER2 expressions were not found to be correlated with tumor grade, P53 expression was associated with poorer prognosis due to higher lymph node involvement and perineural invasion.
 

  1. Harirchi I, Kolahdoozan S, Karbakhsh M, Chegini N, Mohseni SM, Montazeri A, et al. Twenty years of breast cancer in Iran. Ann Oncol 2011;22(1):93-7.
  2.  Ministry of Health & Medical Education. Iranian annual of national cancer registry 2005-2006. Tehran:Tandis;2008.
  3. Omranipour R, Fattahi A. Prevalence of ductal carcinoma insitu of the breast in Tehran University Medical Centers: evaluation of 2244 cases. Tehran Univ Med J 2009;67(7):516-21.
  4. Azizun – Nisa, Bhurgri Y, Reza F, Kayani N. comparison of ER, PR and HER-2 reactiving pattern with histologic grade, Tumor size and lymphocytic status in breast cancer. Asian pac J Cancer Prev 2008;9(4):553-6.
  5. Chen XS, Ma CD, Wu JY, Yang WT, Lu HF, Wu J, et al. Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict the prognosis of breast cancer. Tumori 2010;96(1):103-10.
  6. Fredholm H, Eaker S, Frisell J, Holmberg L, Fredriksson I, Lindman H. Breast Cancer in Young Women: Poor Survival despite Intensive Treatment. PLoS One 2009;4(11):e7695.
  7.  Ambroise M, Ghosh M, Mallikarjuna VS, Kurian A. Immunohistochemical Profile of Breast Cancer Patients at a Tertiary Care Hospital in South India. Asian Pac J Cancer Prev 2011;12(3):625-9.
  8. Pleşan DM, Georgescu CV, Pătrană N, Pleşan C, Stoica D. Immunohistochemical study of p53 and Ki67 in a group of patients with mammary carcinoma. Rom J Morphol Embryol 2010;51(3):459-65.
  9. Hung HJ, Neven P, Drijkoningen M, Parideans R, WildiresH, Berteloot P, et al. Association between Tumor characteristics and HER-2 by immunohistochemistry in 1362 women with primary operable breast cancer. J Clin Pathol 2005;58(6):611-6.
  10.  Sirati F, Ghahri A. Detection of prognostic factors in breast cancer and their relation with menopause and age. Iran J Surg 2007;15(3):41-52.
  11. Taucher S, Rudas M, Mader M R, Gnant M, Dubsky P, Roka S, et al. Do we need HER-2/neu Testing for all patients with primary breast carcinoma. Cancer 2003;98:2547-53.
  12.  Huang HJ, Neven P, Drijkoningen M, Paridaens R, Wildiers H, Van Limbergen E, et al. Hormone receptors do not predict the HER2/neu status in all age groups of women with an operable breast cancer. Ann Oncol 2005;16(11):1755-61.
  13. Huang HJ, Neven P, Drijkoningen M, Paridaens R, Wildiers H, Van Limbergen E, et al. Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related. Breast Cancer Res Treat 2005;91(1):81-7.
  14. Rodrigues NA, Dillon D, Carter D, Parisot N, Haffty BG. Differences in the pathologic and molecular features of intra ductal breast cancer between Younger and older women. Cancer 2003;97(6):1393–1403.
  15. Nayqol J, Nyonqo A, Byakika B, Muchiri L, Cocco M, de Santi MM, et al. Routine assessment of hormonal receptor and HER-2/ neu status underscores the need for more therapeutic targets in Kenyan women with breast cancer. Annal Quant Cyta Histol 2006;28 (2):97–103.
  16. Ivkovic-kapicl T, Knezevic –Usaj S, Djilas-Ivanovic, Panjkovic M. Correlation of HER-2/ neu protein over expression with other prognostic and predictive factors in invasive Ductal breast cancer. Anti Cancer Research 2007;21(4):673-8.
  17. Tokatli F, Altaner S, Usal C, Ture M, Kocak Z, Uyqun K, et al. Association of HER-2 over expression with the number of involved axillary lymph nodes in human receptor positive breast cancer patients. Exp Oncol 2005;27(2):145-9.
  18. Ariga R, Zarif A, Korasick J, Reddy V, Siziopikou K, Gattuso P. Correlation of HER-2/neu gen amplification with other prognostic and predictive factors in female breast carcinoma. Breast J 2005;11(4):278–80.
  19. Guarneri V, Giovannelli S, Ficarra G, Bettelli S, Moiorana A, Piacentini F, et al. Comparison of HER-2 and Hormone receptor expression in primary breast cancer and a synchronous paired metastases: impact on patient management. Oncologist 2008;13(8) 838-44.
  20. Fakheri T, Najafi B, Fadakar soogheh GH. Correlation of P53 Protein Expression with clinicopathologic parameters and Hormonal receptor status in breast carcinoma. Guilan Uni Medical Sci J2006;15(58):1-6.